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Abstract: Silymarin (Sm) is a polyphenolic component extracted from Silybum marianum. 
It is an antioxidant, traditionally used as an immunostimulant, hepatoprotectant, and dietary 
supplement. Relatively recently, Sm has proved to be a valuable chemopreventive and a useful 
antineoplastic agent. Medical success for Sm is, however, constrained by very low aqueous 
solubility and associated biopharmaceutical limitations. Sm flavonolignans are also susceptible 
to ion-catalyzed degradation in the gut. Proven antihepatotoxic activity of Sm cannot therefore 
be fully exploited in acute chemical poisoning conditions like that in paracetamol overdose. 
Moreover, a synchronous delivery that is required for hepatic regeneration is difficult to achieve 
by itself. This work is meant to circumvent the inherent limitations of Sm through the use of 
nanotechnology. Sm nanoparticles (Smnps) were prepared by nanoprecipitation in polyvinyl 
alcohol stabilized Eudragit RS100® polymer (Rohm Pharma GmbH, Darmstadt, Germany). 
Process parameter optimization provided 67.39% entrapment efficiency and a Gaussian particle 
distribution of average size 120.37 nm. Sm release from the nanoparticles was considerably 
sustained for all formulations. Smnps were strongly protective against hepatic damage when 
tested in a paracetamol overdose hepatotoxicity model. Nanoparticles recorded no animal death 
even when administered after an established paracetamol-induced hepatic necrosis. Preventing 
progress of paracetamol hepatic damage was traced for an efficient glutathione regeneration to 
a level of 11.3 µmol/g in hepatic tissue due to Smnps.
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Introduction
Paracetamol (N-acetyl-ρ-aminophenol, APAP) is an antipyretic analgesic, available 
over-the-counter. The drug, however, is toxic in high dosages and an overdose 
of 4 g/day can cause hepatic necrosis.1 APAP hepatotoxicity is marked in alco-
holics and in patients undergoing multiple drug treatment like that in human 
immunodeficiency virus HIV infections or in tuberculosis.2,3 A number of reports 
also exist on suicidal attempts by ingestion of APAP.4 APAP is metabolized in the 
liver to form soluble sulfates and glucuronides. A small amount is converted in the 
microsomal cytochrome P450 enzyme system into the reactive metabolite N-acetyl-
ρ-benzoquinone-imine (NAPQI).5,6 At low dosages, the amount of NAPQI formed gets 
conjugated to the hepatic reduced glutathione (GSH) store, before being eliminated. 
In case of APAP overdose or in conditions when the hepatic GSH store is depleted, 
NAPQI reacts further with cellular proteins causing oxidative stress, microsomal 
membrane damage, and cell death.7 With the liver being the most oxidative organ, 
increased oxidative stress induces apoptosis.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Silymarin (Sm) is a polyphenolic component isolated 
from the fruits and seeds of the milk thistle plant Silybum 
marianum (family Asteraceae).8,9 Milk thistle extracts have 
been used for over 2000 years10 by different civilizations as 
rejuvenators. Chemically, Sm is a mixture of flavonolignan 
isomers11,12 of general molecular formula C25H22O10. Silybin 
constitutes the principal chemical component in the purified 
extract.13
Interest has been renewed in Sm for a variety of 
reasons including the discovery of its chemopreventive, 
anti-angiogenic, and anticancer potentials.14,15 The drug, 
however, suffers from biopharmaceutic limitations due 
to very poor aqueous solubility,16,17 inappropriate tissue 
distribution, and degradation in the gastric environment.18 
Attempts were made to solubulize Sm in order to overcome 
biopharmaceutic limitations but none of these have met 
with any pharmacological successes.19,20 A phospholipids 
complex of silybin was proposed to improve solubility and 
permeability.21 Salts of Sm were attempted but were limited 
by membrane permeability. A liposomal delivery system for 
Sm was reported22 but suffers from high surfactant content 
and low entrapment efficiency.
Sm flavonolignans exert multilateral activity on 
hepatocytes. Sm promotes hepatocyte ribonucleic 
acid  (RNA)  polymerase  I,  facilitates  adenosine 
5′-triphosphatase (ATPase) activity, and restores GSH 
content.23 Hepatoprotection is a synchronous activity of 
flavonolignans to hasten mitotic activity and thereby leads to 
regeneration of liver tissue.24 Additionally, Sm components 
are strong inhibitors of leukotrienes and proinflammatory 
transmitters like nuclear factor kappa B (NF-κB).25,26 Sm 
has great potential for long-term hepatoprotection against 
chemotoxic agents like APAP and might even offset hepatic 
damage.27–29
This work was aimed to develop a slow release nanopar-
ticle delivery device for Sm in order to circumvent solubility 
limitations. Nanoprecipitation technique was preferred over 
others for easy adaptability in scaling up. Eudragit RS100® 
(Rohm Pharma GmbH, Darmstadt, Germany), a   polycationic 
acrylate copolymer, was successfully used for Sm nanopartic-
ulation. The polymer is insoluble at physiological pH ranges 
but swells partially in water. Cationic Eudragit nanoparticles 
allow specific advantages and were previously used in oral 
and ophthalmic nanoparticle delivery devices.30,31 Polyvinyl 
alcohol, PVA, was used as a stabilizer. PVA can provide 
nanoparticle steric and mechanical stabilization32 but has not 
previously been evaluated with Eudragit nanoparticles.
Factorial design experiments were attempted to   optimize 
the nanoparticle size and entrapment efficiency. Both 
protective and restorative animal experiments were used 
to assess the efficacy of Sm nanoparticles (Smnps) as an 
impediment to APAP-induced necrosis. Mouse models were 
preferred over rat, as NAPQI-mediated hepatic damage is 
more pronounced.33,34
Materials and facilities
Borosil® (Mumbai, India) glassware was used for preparation 
and analysis experiments. A precision balance 0.00001 g 
Mettler® Toledo AL54 (Mettler, Columbus, OH), an ultra-
centrifuge Himac CS120GHXL (Hitachi Koki, Tokyo, 
Japan), and Accupipet Tarsons (Tarsons, Kolkata, India) 
were used in preparative processes. Zetasizer® Nano ZS 
(Malvern Instruments, Malvern, UK), UV-vis spectropho-
tometer UV-2550 (Shimadzu, Kyoto, Japan), Atomic Force 
Microscope Nanoscope 3A (Veeco, Plainview, NY), and FT/
IR-670 plus (Jasco, Tokyo, Japan) were used for analytical 
and particle characterization. Homogenizer TH 02 (Omni 
International, Kennesaw, GA) and a microscope (B1 series, 
Motic, Xiamen, China) were used for biochemical analysis 
and animal experiments. Solvents and water used were of 
high-performance liquid chromatography (HPLC) grade 
and were procured from E Merck or Spectrochem (Mumbai, 
India). Dialysis tubing D9652 (MW cut off 12,400 kD), Sm, 
PVA (89,000–98,000 kD), 5,5′-dithiobis (2-nitrobenzoic 
acid) (DTNB) were purchased from Sigma-Aldrich (St 
Louis, MO). Diagnostic kits for biochemical studies were 
obtained from Merck Specialties Private Ltd (Mumbai, 
India). Eudragit RS100® was a gift from Rohm Pharma 
GmbH. Paracetamol was a gift sample from Dey’s Medical 
Stores (Mfg) Ltd (Kolkata, India). Windows Excel (v 2003; 
Redmond, WA) and Sigmaplot (v 6.0; Jandel Scientific) were 
used for most data analysis purposes.
Methods
Preparation of smnps
Smnps were prepared following a nanoprecipitation 
  technique. Different preparations were designed varying 
in stabilizer PVA and the Eudragit RS100® polymer mass 
used (Table 1). In a typical experiment, 10 mg of Sm and 
200 mg of Eudragit RS100® were dissolved together in 
1 mL of ethanol in a sealed glass vial. Nine milliliters of 
2% w/v aqueous solution of PVA was then added slowly with 
magnetic stirring. Stirring was continued for an additional 
period of 10 minutes and 10 mL of water was then added as a International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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nonsolvent for nanoprecipitation. Nanoparticles formed were 
collected by ultracentrifugation at 30,000 rpm for 30 min-
utes at 4°C and the recovery35 recorded was 96 ± 3.9%. The 
particles were resuspended in water, recentrifuged, collected, 
and preserved in vacuum desiccators at 4°C until further 
experiments. Factorial design based experiments (22) were 
carried out to understand effect of change on preparation 
variables, particle size, and Sm entrapment efficiency in 
nanoparticles.
Particle size and polydispersity  
index (PDI)
The particle size of the Smnps was determined by photon 
correlation spectroscopy (PCS) in Zetasizer® Nano ZS 
against a 4 mW helium–neon (He–Ne) laser beam, 633 nm, 
and a back scattering angle of 173°. Particle size and PDI of 
preparations were determined in triplicate.
Zeta potential
Zeta potentials were measured using the Zetasizer® Nano ZS 
using disposable zeta cells. Aliquots from each preparation 
type were injected in electrophoretic zeta cells and zeta poten-
tials were analyzed using the Smoluchowski equation.
Atomic force microscopy (AFM)
The morphological examination of the nanoparticles was 
carried out using a AFM setup. Smnp suspensions (100 µL) 
from different preparations were deposited onto fused mica 
substrates and the particles were visualized in tapping mode 
using RTESP tips (Veeco, Santa Barbara, CA) at 267–328 
kHz resonance frequency at a scan speed of 1.2 Hz.
Fourier transform infrared (FTIr) 
spectroscopy
FTIR studies were carried out to observe for Sm and polymer 
interactions if any. Samples of Sm, Eudragit RS100®, and 
an eutectic mixture were diluted separately with IR grade 
KBr in the ratio of 1:100 and were pelletized in a hydraulic 
press. The pellets were scanned over a wavenumber range of 
4000–400 cm−1 and the data stacked in KnowItAll® (Bio-Rad, 
Hercules, CA) software to compare and search for chemical 
interactions.
Nanoparticle entrapment efficiency
Sm mass encapsulation in nanoparticle was determined 
from the amount of Sm originally taken and the amount 
remaining in the supernatant after harvesting. A validated 
spectrophotometric analysis method was used throughout. 
Briefly, 100 µL of supernatant from each preparation was 
diluted in pH 7.4 phosphate buffer: methanol, 48:62, v/v 
and Sm λmax of 326 nm was used for analysis.36 The limit of 
determination (LOD) for Sm was observed as 1.167 µg/mL 
and the limit of quantitation (LOQ) was 3.896 µg/mL. Sm 
entrapment efficiency for each preparation was determined 
using the formula:
Sm entrapment 
Mass of Sm originally taken   Mass of Sm
% ()
=
−    in supernatant
Mass of Sm originally taken

 

  ×100
In vitro release studies
Smnp equivalent to 5 mg of payload was suspended in 5 mL 
of 100 mM, pH 7.4 phosphate buffer and transferred quan-
titatively in dialysis bags. Lightly tied bags were placed in 
glass vials containing 100 mL of phosphate buffer maintained 
at 37°C over a shaking water bath set at 50 rpm. At every 
predetermined time interval, 5 mL of the buffer medium 
was withdrawn from the external media and 20 mL of fresh 
buffer was added to maintain sink conditions. The amount of 
Sm released at each time point was estimated spectrophoto-
metrically as described earlier with necessary corrections 
for the dilution factors. The in vitro release studies for all 
preparations were completed in triplicate and the cumula-
tive percentage release over time was plotted. In order to 
understand the release mechanism, the Korsmeyer–Peppas 
model was applied and release exponent (n) and the constant 
Table1 Particle size, zeta potential, and silymarin entrapment in nanoparticles
Preparation 
type
Silymarin  
mass (mg)
Eudragit RS  
100 (mg)
PVA  
(% w/v)
Silymarin 
entrapment* %
Particle  
size* (nm)
PDI* Zeta  
potential* (mV)
B1 10 200 4 55.10 ± 1.12¥   89.86 ± 4.27¥ 0.255 ± 0.02 +17.60 ± 1.21
B2 10 200 2 67.39 ± 4.32¥ 120.37 ± 2.11§ 0.262 ± 0.01  + 27.7 ± 2.67
B3 10 100 4 55.27 ± 5.68¥ 100.08 ± 3.30¥ 0.257 ± 0.03  + 23.2 ± 3.55
B4 10 100 2 34.75 ± 3.18 132.46 ± 5.25 0.344 ± 0.06  + 29.5 ± 1.08
Notes: *results expressed as mean ± sD (n = 3); ¥P , 0.01 significant difference compared with B4; §P , 0.05 no significant difference compared with B4. 
Abbreviations: PDI, polydispersity index; PVA, polyvinyl alcohol; sD, standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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incorporating structural and geometric characteristics of the 
system (K) values were calculated using SigmaPlot.
Smnp in APAP-induced 
hepatotoxicity
Animal care
Swiss albino mice (25–30 g) procured from Central Research 
Institute (Kolkata, India) were used in all experiments. 
  Animals were housed in polypropylene cages in standard 
  laboratory conditions of relative humidity 50% ± 10%, 
temperature 22°C ± 2°C, and 12/12 hour light–dark cycle 
for 10 days prior to experiments. Access of water was 
ad   libitum and standard pellet food (Hindustan Unilever, 
Mumbai, India) supply was provided twice a day. All animal 
experiments were conducted as per the approval and guide-
lines of the institutional animal ethical committee under 
the Government of India registration number 506/01/a/
CPCSEA. Mice were fasted for 12 hours before the start of 
experiments in order to deplete hepatic GSH store. APAP 
and test drugs were administered intraperitoneally (i.p.) 
either dissolved or dispersed in saline at 37°C. Food was 
restored 1 hour after administration; water, however, was 
allowed ad libitum.
APAP hepatotoxicity
Animals were individually weighed and randomly divided 
into 12 animals per group. Group A, received normal saline 
and served as the control. APAP hepatotoxicity was induced 
in Group B animals by single i.p. injection of 300 mg/kg37 
and served as positive control. Group C mice were treated 
with empty nanoparticles on alternate days for 7 days, prior 
to administration of APAP. Effects of Sm and Smnp over 
APAP-induced hepatotoxicity were analyzed. An alternate 
day treatment protocol was followed in Group D animals 
receiving 125 mg/kg of Sm for 7 days38 prior to a single 
injection of 300 mg/kg APAP. Similarly, Group E animals 
were treated with Smnp with an equivalent of 125 mg/kg Sm 
payload for 7 days prior to an injection of APAP. Group F 
animals received a single injection of 125 mg/kg Sm 1 hour 
after APAP-induced hepatotoxicity while group G animals 
received a single injection of Smnp equivalent to 125 mg/kg 
of Sm payload 1 hour after APAP administration.
After 12 hours of APAP injection, animals were 
  anesthetized with anesthetic ether and blood was collected 
and allowed to coagulate at room temperature. Serum was 
separated and stored at −80°C for biochemical evaluations. 
Mice were then euthanized with ether overdose and the liver 
removed. Portions of the liver from both lobes were quickly 
dissected, blotted, weighed and stored in −80°C. A portion of 
the liver was preserved in formalin for histological   sections. 
Tissue homogenates (10% w/v) were prepared in ice cold 
phosphate buffer (50 mM, pH 7.0) containing 0.1 mM 
  ethylenediaminetetraacetic acid (EDTA). Homogenates were 
further centrifuged at 5000 rpm for 15 minutes at 4°C and the 
supernatant was stored at −80°C until further use.
Biochemical parameters  
and histopathology
Biochemical evaluations for hepatic injury were recorded 
by assessment of different enzyme markers in serum using 
specific reagent kits. Analytical procedures were followed as 
directed in the kits. Reduced GSH level was measured from 
liver homogenate following Ellman’s method.39 Standard 
slide preparation techniques were followed for histology and 
visualization after staining with hematoxylin and eosin.
statistical analysis
All experiments were completed in triplicate unless mentioned 
otherwise and the results were presented as mean ± standard 
deviation. Graphs were plotted with the mean values includ-
ing the error bars. Statistical differences of mean values were 
analyzed using Student’s t-test.   Differences were considered 
significant when P , 0.01.
Results
Limited solubility and specific polymer association were 
the major challenges in Sm nanoparticulation. Among 
many techniques available for drug nanoparticulation; 
nanoprecipitation takes an interesting advantage of solubility 
gradient by controlled deposition of both polymer and the 
drug payload.32 The technique also appeared simple and 
reproducible for later application. The current study has 
utilized the similar solubility characteristics of polymer 
Eudragit RS100® and Sm.31,17,18 Eudragit RS100® has widely 
been used for ocular nanoparticle drug delivery with good 
pH stability, biocompatibility, and localization properties.40 
PVA was used as an efficient stabilizer as it can entrap an 
array of Eudragit nanoparticles.
There were only a limited number of variables in the nano-
precipitation technique. A 22 factorial design study was run 
to study the effect of Eudragit and PVA mass as independent 
variables on nanoparticle size and Sm entrapment efficiency. 
High–low combination batches were tested and particle size, 
zeta potential, and PDI were recorded (Table 1).
Particles in the vicinity of 100 nm have a higher possibility 
for specific tissue localization.41 Preparations B2, B3, and B4 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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were in the appropriate size range for localization in the 
liver, whereas preparation B2 carried a higher Sm load. The 
nanoparticles carried a small positive charge due to a com-
bined effect of the cationic polymer Eudragit RS100® and 
the associated stabilizer PVA. A small surface charge was 
instrumental to keep the nanoparticles stable in solution.
Factorial design
A 22 (two level two factors) factorial design study was used 
to understand the effects of two independent variables, the 
amount of Eudragit RS100® mass (X1) and the proportional 
amount of PVA (X2) used over the nanoparticle size range 
and Sm mass entrapment efficiency.42 Results are expressed 
in equation (1):
 Y i = b0 + b1X1 + b2X2 + b12X1X2  (1)
where, b0 is the arithmetic mean response for four different 
preparations and bi (i = 1, 2) is the estimated coefficient for the 
factors Xi (i = 1, 2). Xi (i = 1, 2) denote the effect of changing 
one factor at a time from its lowest to highest level. The inter-
action terms X1X2 signify the effect when both the factors were 
changed simultaneously. Yi denotes the observation terms 
of either the particle size or the Sm percentage entrapment 
efficiency. The values of F were much higher than the critical 
value for both observation parameters, indicating significance 
of the model. The final equation regression parameter (R2) and 
P-values were in agreement with the model parameters and 
are shown in Table 2. PVA percentage had a highly significant 
effect on particle size. The size of nanoparticles made using 
the nanoprecipitation technique could be controlled by PVA 
proportion and the mass of polymer incorporated. The inter-
action effect was negligible and did not pass the significance 
test (Table 3). Both the PVA concentration and the Eudragit 
mass had a positive impact on Sm entrapment. The effect of 
the interaction term was, however, noticeable while consider-
ing the Sm entrapment percentage.
AFM studies
Smnps were evenly distributed in AFM with almost no 
aggregation. Particles from all preparation types appeared 
spherical and smooth in surface. AFM study samples from 
all four preparations are depicted in Figure 1.
FTIr studies
Sm flavonolignans were evidenced using FTIR analysis by the 
typical presence of benzopyran ring vibrations at 1084 cm−1 
with concomitant presence for out of plane —C—H 
  deformations at 821 cm−1 (Figure 2). The reactive flavono-
lignan ketone43 responded at 1636 cm−1 and the aromatic ring 
stretching vibrations were observed at 1509 cm−1. Eudragit 
RS100® polymer linear branch ketone responded at 1733 cm−1 
which associated with linear —C—H stretching vibrations 
at 2849 cm−1. When an eutectic mixture of Sm and Eudragit 
polymer was analyzed using FTIR, the Sm ketone was unaf-
fected at 1636 cm−1 alongside the polymer ketone stretching 
at 1733 cm−1, indicating no chemical interaction between Sm 
and the polymer. In addition, the structurally sensitive Sm 
benzopyran at 1084 cm−1 and specific Eudragit response at 
2849 cm−1 were observable in the Sm-Eudragit blend, which 
suggests no chemical interactions.
In vitro release
In vitro release was gradual over time. In the case of 
Smnp B1 and B2, an initial faster Sm release phase was 
observed over a period of 8 hours. This was possibly due 
to nanoparticle surface-adsorbed Sm molecules. Release 
thereafter was steady and 90% of the load entrapped was 
traced during the study period of 200 hours. Preparation 
B1 and B2 release were persistent whereas B4 release was 
not very stable (Figure 3). Polymer mass here appeared an 
important parameter for Sm entrapment and release profil-
ing and no polymer burst effect was observed during the in 
vitro release studies. Korsmeyer–Peppas kinetic model was 
applied for Smnp release up to 60% of the mass load release. 
The exponent component n for B2 and B3 formulation was 
near 0.4 (Table 4), thus indicating a diffusion-controlled 
release pattern.44 Sm mass loading in preparation B2 was 
significantly higher and the B2 in vitro release profile was 
sufficiently consistent. Smnps of B2 type were therefore 
chosen for a detailed hepatoprotection evaluation against   
APAP-induced hepatotoxicity.
Table 2 summary of regression analysis and ANOVA for measured responses
Observation parameter Y b0 b1 b2 b12 R2 F P€
silymarin entrapment % 53.13 2.06 8.12 −8.20 0.9464 53.93 ,0.0001
Particle size nm 110.70 −15.72 −5.58 +0.47 0.9578 69.08 ,0.0001
Note: €P , 0.0001 indicates highly significant.
Abbreviation: ANOVA, analysis of variance.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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APAP hepatotoxicity and liver 
biochemistry
Effects of Sm and Smnp on APAP mouse hepatotoxicity 
are presented in Table 5. A dose of 300 mg/kg (Group B) 
established significant hepatotoxicity as evidenced from the 
elevated levels of marker enzymes compared with the control 
Group A. Mortality was recorded in the APAP-treated group. 
Sm pretreatment (Group D) provided quantitative protection 
against hepatotoxicity as shown by reduced levels of marker 
enzymes. Empty nanoparticles without Sm load, however, 
did not mark any significant change in serum parameters. 
Pretreatment with Smnp (Group E) endowed a significant 
reversal of marker enzymes when compared with the APAP-
treated group. Additionally, no animal death was recorded 
in group E.
The levels of reduced GSH in the APAP-treated group 
were markedly low at 6.9 ± 1.21 µmol/g of tissue. This was 
indicative of NAPQI-mediated damage. In the case of Group 
D and E, the reduced GSH level was restored to a higher level 
possibly due to a Sm-mediated regeneration response.
A differential response was recorded when the group F 
and group G animals were administered with Sm or Smnp 
1 hour after APAP overdose. Sm failed to elicit significant 
hepatoprotection. The APAP-elevated levels of marker 
enzymes and the hepatic GSH levels were not significantly 
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Figure 1 AFM study of silymarin nanoparticle preparations. Preparation B1 (A), Preparation B2 (B), Preparation B3 (C), Preparation B4 (D).
Abbreviation: AFM, atomic force microscopy.
Table 3 effects of process variables on silymarin entrapment and 
particle size
Parameter 
terms
Process 
variables
Effect on  
particle size
Effect on Sm 
entrapment
P¶
b1 %PVA −15.72 ,0.0001
b2 eudragit 
amount
−5.58 ,0.0030
b12 Interaction +0.47 ,0.6992
b1 %PVA +2.06 ,0.0668
b2 eudragit 
amount
+8.12 ,0.0001
b12 Interaction −8.20 ,0.0001
Notes: ¶P , 0.01 indicates significant; P , 0.0001 indicates highly significant. 
Abbreviations: PVA, polyvinyl alcohol; sm, silymarin.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 2 FTIr overlay for silymarin and eudragit rs100®. FTIr scan over the entire region (A), comparison zone upfield (B), comparison zone downfield (C).
Notes: color codes – silymarin (brown); eudragit rs100® (green); silymarin-eudragit rs100® (blue).
Abbreviation: FTIr, Fourier transform infrared.
Table 4 Korsmeyer–Peppas release kinetics for nanoparticles
Preparation code Korsmeyer–Peppas model 
parameters
n value K value
B1 0.35 0.1172
B2 0.39 0.1099
B3 0.41 0.0825
B4 0.52 0.0420
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Figure 3 In vitro release studies of silymarin nanoparticles.
altered. In the case of Smnp, however, hepatic GSH store 
was restored with concomitant decrease in serum marker 
enzymes. Perhaps Smnps hepatoprotection was possible due 
to the rapid localization of nanoparticles in hepatic tissues 
during the 12-hour exposure period.
histopathology
Elevated levels of marker enzymes in serum were an indi-
cation of disrupted structural integrity of the hepatocellular 
membrane which caused leakage of the liver enzymes into the 
blood due to APAP toxicity. APAP-treated group (Group B) 
animals demonstrated loss of normal hepatic structure, with 
necrotic damage which was characterized by the disruption of 
the lattice nature of the hepatocyte, damaged cell   membranes, 
reduced diameter of nuclei, disintegrated central vein, 
dilated sinusoids and moderate infiltration of monocytes, and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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neutrophils in the cytoplasm (Figure 4B). The Sm-treated 
group (Group D) showed improved histological changes in 
comparison to Group B animals. This was implied by the 
presence of mild necrotic lesions (Figure 4D). Smnp-treated 
groups (Figures 4E and 4F), however, showed significant 
regeneration, visible by the presence of increased numbers of 
hepatocytes and lack of any prominent centrilobular necrosis 
or sinusoidal congestion. The inflammatory cell infiltration 
caused by APAP was also significantly decreased following 
Smnp treatment.
Discussion
Antihepatotoxic activity of Sm is due to a synchronous effect of 
principal flavonolignans.45 Our initial attempts in Sm nanopar-
ticulation with poly(lactic-co-glycolic acid) (PLGA),46 casein, 
and alginate47 were unsuccessful due to very low Sm mass 
loading. Eudragit RS100® is a safe and biocompatible polyca-
tion and has previously been used in ophthalmic nanoparticle 
delivery devices.31,48 PVA resulted in a lowering of interfacial 
tension and nanoparticle steric and mechanical stabilization.32 
The effect of PVA concentration in particle sizing was shown 
in factorial design experiments. Higher initial concentration 
of PVA resulted in smaller particles. Similar PVA-induced 
stabilization effects have been reported by others in the case 
of PLGA nanoparticles.49,50 Sm payloading on the other hand 
was not dependent on any one parameter and the effect of 
the interaction term was significant. AFM details indicated 
smooth and spherical particles in all cases of PVA stabilized 
Eudragit nanoparticles. Chemical interaction studies in FTIR 
indicated no significant peak shifts for Sm in the presence of 
the entrapment polymer Eudragit RS100®.   Structurally reac-
tive Sm ketone and benzopyran groups responded strongly at 
1636 cm−1 and 1084 cm−1, both as free compounds and in the 
Eudragit polymer mixture environment.
Smnps exhibited a sustained release profile and type 
B1 and B2 accounted for a 90% payload release during 
the 200 hours of the in vitro study period. The biphasic Sm 
release was possibly due to nanoparticle surface-adsorbed 
molecules, low aqueous solubility of Sm, and the insoluble 
nature of the polymer. Smnp B2 type carried a higher pay-
load and was selected for detailed APAP-induced mouse 
hepatotoxicity studies.
APAP hepatotoxicity is primarily due to the pharma-
cokinetic generation of the reactive metabolite NAPQI.5 
NAPQI binds to cellular macromolecules causing the col-
lapse of cell membranes and subsequent cell death. A dose 
of 300 mg/kg APAP resulted in profound hepatotoxicity and 
correlated well with the rise in serum aspartate transami-
nase (AST), 4943.3 ± 220.5 IU/L, and alanine transaminase 
(ALT), 5161.7 ± 339.8 IU/L levels. Test compounds were i.p. 
administered and the serum enzyme levels were monitored 
as markers for hepatic conditions. Hepatic GSH store was 
monitored (Table 5), as the increased level of NAPQI is linked 
directly to depletion of hepatic GSH store.6 APAP inflicted 
a rapid depletion of GSH store within 1 hour of treatment.51 
Higher doses of APAP generate NAPQI, an oxidative product 
of cytochrome p450, in hepatocytes. GSH can neutralize the 
highly electrophilic NAPQI but in conditions of depleted 
GSH stores, NAPQI leads to a cascade of adverse events lead-
ing to the generation of reactive oxygen species, membrane 
protein damage, and adenosine triphosphate (ATP) depletion 
leading to hepatic necrosis.52 Other contributing factors for 
APAP necrosis are intracellular Ca2+ imbalance and activa-
tion of inflammatory mediators such as tumor necrosis factor 
alpha (TNF-α).6,53
Sm possesses strong free radical scavenging activity, 
inhibits lipid peroxidation, and promotes regeneration of 
damaged hepatocytes. This effect is due to the increased 
synthesis rate of ribosomal RNA (rRNA) for the activa-
tion of RNA polymerase. In addition, Sm inhibits the 
5-lipoxygenase pathway and prevents liver fibrosis. Sm 
also possesses membrane stabilizing properties54 and 
Table 5 effects of silymarin and silymarin nanoparticles against APAP-induced hepatotoxicity
Animal 
groups
AST¶ (IU/L) ALT¶ (IU/L) ALP¶ (IU/L) GSH¶ (μmol/g  
of tissue)
Mortality 
(dead/total)
A   51.7 ± 3.2ℵ   86.2 ± 8.6ℵ   116.2 ± 8.6ℵ 16.8 ± 0.3ℵ 0/12
B 4943.3 ± 220.5 5161.7 ± 339.8 2161.7 ± 129.1   6.9 ± 1.21 6/12
c 4703.2 ± 392.3¥ 5015.0 ± 411.6¥ 2065.0 ± 178.1¥   6.7 ± 1.5ζ 6/12
D   700.7 ± 46.9ℵ   785.2 ± 85.5ℵ   385.2 ± 35.7ℵ 13.8 ± 1.4ℵ 0/12
e   352.4 ± 77.9ℵ   437.2 ± 87.8ℵ   237.3 ± 27.8ℵ 14.6 ± 1.3ℵ 0/12
F 3956.2 ± 250.8ℵ 4371.4 ± 229.5ℵ 1861.2 ± 109.5ℵ   8.3 ± 0.7ℵ 4/12
g   553.1 ± 25.1ℵ   581.8 ± 33.7ℵ   395.7 ± 33.2ℵ 11.3 ± 0.9ℵ 0/12
Notes: ¶results expressed as mean ± sD (n = 12); ℵP , 0.01 significant difference compared with Group B; ¥P , 0.5 no significant difference compared with Group B;   
ζP , 0.8 no significant difference compared with Group B.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; APAP, paracetamol; AsT, aspartate transaminase; gsh, glutathione; sD, standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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these factors together contribute to its hepatoprotective 
activity.
Group D and group E animals pretreated with Sm or 
Smnp did not show a marked increase in serum marker 
enzymes. Hepatic GSH level did not decline and 100% sur-
vival was recorded. Smnp provided an incremental improve-
ment over Sm in serum marker enzyme levels. This was 
likely due to Sm-induced membrane stabilization effects. 
These observations corroborated well with the histological 
examinations of treated and control groups (Figure 4B, 4E, 
and 4F). However, when Sm was administered 1 hour after 
established APAP-induced hepatic necrosis55 there was no 
significant lowering of serum marker enzymes. Necrosis and 
damage were also observed in the liver. Animal mortality 
A
C
E
B
D
F
Figure 4 Liver histology (10×) in mice. Normal control (A), APAP only treated (B), APAP on silymarin pretreatment (C), APAP on silymarin nanoparticle pretreatment (D), 
silymarin posttreatment and APAP (E), silymarin nanoparticle posttreatment and APAP (F).
Abbreviation: APAP, paracetamol.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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recorded was significant and comparable to that of group B. 
Group G animals, however, when treated with Smnp 1 hour 
after APAP challenge survived and serum transaminase fac-
tors reverted to a lower concentration. A significant amount 
of hepatic GSH was also recorded.
Sm is membranotropic in nature, and Sm flavonolignans 
are known to exert a differential hepatic membrane stabi-
lization response.54 Silibin, a major component of Sm, is 
known to induce dual perturbation on membrane   bilayers.56 
Silibin effects a concentration-dependent transition of 
bilayers to micellar structure. Isolated membrane studies 
have provided ample evidence that Sm prevents membrane 
disruption with increasing concentration. Silibin protective 
effects were, however, far less marked and were independent 
of the concentration gradient. Nanoparticle synchronous 
delivery therefore is important and exerts hepatoprotec-
tion activity in case of APAP overdose. Moreover, it can be 
reasoned that Smnp-induced rapid replenishment of hepatic 
nonprotein-SH concentration was due to particle effects. 
Sm flavonolignans are known to increase nuclear rRNA 
synthesis to a   significant level within 8 hours of injection.23 
  Biopharmaceutic enhancement of Sm through nanoparticula-
tion can therefore provide a significant solution for conditions 
of acute APAP poisoning.
Conclusion
A new nanoparticle delivery device for Sm in Eudragit 
RS100® was successfully designed and protective properties 
against APAP-induced hepatotoxicity were established. 
Increased Smnp-induced rapid regeneration of hepatic GSH 
levels was demonstrated, along with downregulation of serum 
enzyme parameters, and marked increase in   survival even 
when administered after APAP-induced hepatic damage. 
This appeared possible due to nanoparticle-assisted improved 
solubilization of Sm.
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